TARRYTOWN, N.Y., April 17, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and its collaborator Bayer today announced that aflibercept 8 mg and EYLEA® (aflibercept) Injection ...
People with diabetic macular edema may get eye injections to help control their symptoms. These eye injections can improve vision and also stop the damage that causes vision to get worse. Most of ...
TARRYTOWN, N.Y., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA ® (aflibercept) ...
TARRYTOWN, N.Y., Oct. 21, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has granted pediatric exclusivity for EYLEA ® ...
Eylea (aflibercept) injections can cause both mild and serious side effects, though serious side effects are rare according to clinical trials. Mild side effects include eye floaters, redness, and ...
Supplementary biologics license application planned for submission to the U.S. Food and Drug Administration in the first quarter of 2025 “All currently FDA-approved anti-VEGF therapies for retinal ...
89% and 84% of patients were maintained on ≥12- and ≥16-week dosing intervals, respectively, throughout the two-year period, while sustaining their vision and anatomic improvements At two years, 44% ...
Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular degeneration (wAMD). The findings, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results